Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMNM with… →

IMNM Key Statistics

As of Sep 4, 2026

Trading

Open: $26.68
Previous Close: $27.16
Day's Range: 26.66–27.14
52-Week Range: 8.67–30.06
Volume: 562.30K
Beta: 2.13

Valuation

Market Cap: $3.04B
P/E Ratio: unprofitable
EPS (ttm): −2.49

Financials (FY)

Revenue (FY): $6.94M−23.23%
Net Income (FY): −$212.39M
Profit margin: 0.00%
Shares Outstanding: 113.58M
1-Year Return: +173.06%

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 1.35M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IMNM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−28.03%+33.88%−82.95%+384.16%−0.75%+102.26%+24.58%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	+24.58%
2025	+102.26%
2024	−0.75%
2023	+384.16%
2022	−82.95%
2021	+33.88%
2020 (partial year)	−28.03%

As of September 4, 2026.

IMNM Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$6.94M	−$212.39M	−3060.0%
2024	$9.04M	−$292.96M	−3240.4%
2023	$14.02M	−$106.81M	−761.9%
2022	$0.00	−$36.90M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$6.94M	—	−$224.11M	−$212.39M	−3060.0%
2024	$9.04M	—	−$153.46M	−$292.96M	−3240.4%
2023	$14.02M	—	−$28.73M	−$106.81M	−761.9%
2022	$0.00	—	−$36.90M	−$36.90M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IMNM Valuation vs Biotechnology Median

Median of 656 stocks

Metric	IMNM	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Immunome, Inc. (IMNM) carries a market capitalisation of $3.04B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 247 employees.

Over the past 52 weeks the price has ranged from $8.67 to $30.06. The most recent close on file for IMNM is $26.76, dated September 4, 2026. That is −$0.40 (−1.47%) against the previous close. The latest close sits 208.83% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $6.94M. Against the prior fiscal year total of $9.04M, that is a change of −23.23%. The same year closed with a net loss of $212.39M. The reported profit margin is 0%. Trailing earnings per share are −2.49.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $6.94M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is +173.06%. Measured over 5 years, that is +12.12% a year compounded. Beta against the wider market is reported at 2.13. Annualized volatility over the trailing 5 years is 89.24%.

Growth & Income

No dividend is on file for IMNM.

2026 is still running; the price is +24.58% year to date. The strongest complete calendar year on file is 2023 at +384.16%; the weakest is 2022 at −82.95%. Of the 5 complete calendar years on file, 3 finished higher.

Peer Comparison

Immunome, Inc. (IMNM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Immunome, Inc.	IMNM	$3.04B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Immunome, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Immunome, Inc.

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Visit website →

Immunome, Inc. (IMNM) Stock Analysis